Key takeaways
- • $199–249/mo compounded — Henry Meds’ published prices on 15 May 2026, no separate membership.
- • Not FDA-approved as finished product — compounded under 503A loophole, not full safety review.
- • FDA warning letters to compounded GLP-1 sellers in 2026 — none naming Henry Meds on 16 September 2026.
- • Established brand since 2022 — longer track record vs newer entrants.
- • No direct insurance handling — pure cash-pay model.
What Henry Meds is
Henry Meds is a telehealth platform launched 2022 specializing in compounded GLP-1 medications. Operates with licensed US providers + 503A-licensed compounding pharmacies. Cash-pay only — no insurance handling. Brand recognition in compounded category competitive with Eden, SkinnyRx, MEDVi.
Pricing breakdown
| Drug | Monthly |
|---|---|
| Compounded semaglutide — entry / starter | $149–199/mo |
| Compounded semaglutide — maintenance | $299/mo |
| Compounded tirzepatide — starter | $299/mo |
| Compounded tirzepatide — maintenance | $399/mo |
What Henry Meds does well
70-80% cheaper than brand cash list price
Established compounded brand since 2022
Async-first model — fast intake to Rx
Tirzepatide compounded option (less common vs semaglutide)
No insurance friction — pure cash-pay simplicity
Provider network in all 50 states
Where Henry falls short
Compounded = NOT FDA-approved as finished product
FDA enforcement of compounded GLP-1 marketing applies
No insurance integration — full cash burden
Cancellation difficulty reported in Trustpilot
No labs included — bare-bones service
Limited customer service depth vs Hims/Ro
Who Henry is best for
Best fit: Cash-pay patients accepting FDA enforcement risk for 70-80% savings vs brand. Patients wanting established compounded brand with track record. Tirzepatide patients (compounded supply less common vs semaglutide).
Poor fit: Insurance-covered patients (Ro/Hers brand path cheaper net). Risk-averse patients. Patients wanting labs/coaching. Patients near major FDA enforcement zones.
Henry Meds vs. other GLP-1 providers — compare
SponsoredSee how Henry Meds stacks up against other telehealth GLP-1 providers. Partner offers first — we earn a commission from those — then ranked by our editorial score. Visit a partner to check current pricing and eligibility — we compare and link, we never sell medication.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you. Partner offers are listed first; payment never changes a score. How we make money
- Sesame Care· from $208/moTop ratedTelehealth · online visit
- SkinnyRx· from $199/moCompounded not offered in AL, LA, MS — check before startingTelehealth · online visitCompounded · not FDA-approved
- Enhance MD· price shown after their intakeNo lab work to startRestricted in AL, AR, GA, HI, LA, MS, MO, ND, SC, TN, WV — check before startingTelehealth · online visitCompounded · not FDA-approved
- HealthRX· from $165/moLowest starting pricemonthly Subscribe & Save ($149 first month); $99/mo on the 12-month plan, $1,188 upfrontTelehealth · online visitCompounded · not FDA-approved
FAQ
Is Henry Meds legit?
Henry Meds is an operating telehealth company that prescribes compounded semaglutide and tirzepatide. We do not recommend it: the BBB rates it F and recorded no responses to consumer complaints (4 June 2026). Compounded GLP-1s are not FDA-approved as finished products.
What does Henry Meds cost?
When we last read Henry Meds’ published prices (15 May 2026), compounded semaglutide started at $199/mo and compounded tirzepatide at $249/mo, with no separate membership fee. Prices change, so confirm on Henry Meds before paying. For comparison, FDA-approved Wegovy is about $349/mo at maintenance doses through NovoCare self-pay.
Is compounded semaglutide safe?
Compounded semaglutide is pharmacy-mixed under section 503A — bypasses FDA finished-product safety/efficacy review. Active ingredient is same molecule. Risks: dose accuracy variance, injection site reactions, contamination if pharmacy QC weak. Henry uses 503A-licensed pharmacies, but FDA explicitly warns against compounded GLP-1 outside of acute drug shortage (which ended April 2025 for semaglutide, March 2025 tirzepatide).
Has FDA warned Henry Meds?
Not that we can find. A search of FDA’s warning-letter database on 16 September 2026 returned no letter naming Henry Meds. FDA has warned other compounded GLP-1 telehealth sellers, including SkinnyRx and MEDVi (letters dated 20 February 2026) and Eden (8 June 2026). Room to compound semaglutide and tirzepatide narrowed once the FDA shortages ended in 2024–2025.
How does Henry compare to Eden?
Both sell compounded semaglutide and tirzepatide for cash, and we recommend neither. Henry Meds is rated F by the BBB, which recorded no responses to consumer complaints; Eden holds an open FDA warning letter (728279, issued 8 June 2026). On price, Eden requires a $99/month membership on top of medication, so its starting cost is $198/month; Henry Meds charged no separate membership when we last checked its prices.
What if I want to switch to brand later?
Easy — switch to Ro, Hers, or LifeMD after insurance verification. Stop Henry monthly billing first; new provider intake reviews your prior dose to maintain titration level. No medical interruption needed.
Bottom line
Henry Meds delivers compounded GLP-1 access at 70-80% brand savings — real cost win if you have not insurance coverage and accept FDA enforcement risk. Brand-name path (Ro/Hers) safer regulatory but much pricier without insurance. Full ranking.
Sources
Editorial only — not medical advice. Pricing accurate as of 2026-06-05; verify with Henry before deciding.